TY - JOUR T1 - Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. AU - Meunier,P J, AU - Roux,C, AU - Ortolani,S, AU - Diaz-Curiel,M, AU - Compston,J, AU - Marquis,P, AU - Cormier,C, AU - Isaia,G, AU - Badurski,J, AU - Wark,J D, AU - Collette,J, AU - Reginster,J Y, Y1 - 2009/01/20/ PY - 2008/07/18/received PY - 2008/12/04/accepted PY - 2009/1/21/entrez PY - 2009/1/21/pubmed PY - 2011/1/14/medline SP - 1663 EP - 73 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 20 IS - 10 N2 - SUMMARY: Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/19153678/Effects_of_long_term_strontium_ranelate_treatment_on_vertebral_fracture_risk_in_postmenopausal_women_with_osteoporosis_ L2 - https://doi.org/10.1007/s00198-008-0825-6 DB - PRIME DP - Unbound Medicine ER -